Enzon Extends Exchange Offer Amid Pending Viskase Merger

The latest announcement is out from Enzon Pharmaceuticals ( (ENZN) ).

On March 16, 2026, Enzon Pharmaceuticals announced it has extended the expiration date of its exchange offer to holders of its Series C Non-Convertible Redeemable Preferred Stock, who are being offered Enzon common shares in exchange for their preferred holdings. The offer will now expire at 5:00 p.m. Eastern time on March 19, 2026, unless further extended, and forms part of the broader capital and corporate restructuring associated with Enzon’s planned merger with Viskase Companies, Inc., for which a detailed registration statement containing information on the combined company has been filed with the SEC. The announcement underscores that the merger remains subject to various closing conditions and regulatory and shareholder approvals, and highlights a wide range of transaction risks, including timing uncertainties, potential litigation, operational disruptions, and the possibility that expected financial and strategic benefits of the combination may not be realized, factors that are material for current and prospective stakeholders evaluating Enzon’s evolving risk profile and ownership structure.

More about Enzon Pharmaceuticals

Enzon Pharmaceuticals operates in the pharmaceutical and biotechnology industry, historically focused on developing and commercializing therapeutics, with its securities traded on over-the-counter markets. The company is currently pursuing a strategic combination with Viskase Companies, Inc., aiming to create a combined entity whose common stock is expected to be quoted on the OTCQB tier, subject to customary conditions and approvals.

Average Trading Volume: 71,919

Technical Sentiment Signal: Sell

Current Market Cap: $4.23M

For a thorough assessment of ENZN stock, go to TipRanks’ Stock Analysis page.